Boston Scientific (NYSE:BSX) Director Cheryl Pegus Purchases 1,770 Shares

Boston Scientific Corporation (NYSE:BSX) Director Cheryl Pegus purchased 1,770 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the acquisition, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This trade represents a ? increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Boston Scientific Price Performance

Shares of BSX opened at $57.08 on Friday. The firm has a market cap of $84.84 billion, a PE ratio of 23.88, a PEG ratio of 1.04 and a beta of 0.62. The firm’s 50 day moving average price is $62.21 and its 200 day moving average price is $80.40. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a twelve month low of $52.52 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has authorized a stock repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Multiple Boston Scientific directors bought shares this week, including David C. Habiger, Edward J. Ludwig, and Cheryl Pegus. Heavy insider buying is often seen as a vote of confidence from management and can boost investor sentiment. Article Title
• Positive Sentiment: Boston Scientific reported positive pivotal trial results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter, with the FRACTURE trial meeting all primary safety and effectiveness endpoints. That strengthens the case for future regulatory approval and supports the company’s growth story. Article Title
• Neutral Sentiment: Baird kept an Outperform rating on BSX but trimmed its price target to $75 from $78, suggesting Wall Street still likes the name even as expectations are being adjusted. Article Title
• Negative Sentiment: Some recent commentary said Boston Scientific fell due to weak results, which may be weighing on sentiment and reminding investors that the stock has faced pressure despite longer-term growth prospects. Article Title

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors have recently modified their holdings of the company. Compass Capital Management Inc. raised its position in shares of Boston Scientific by 21.7% in the first quarter. Compass Capital Management Inc. now owns 710,874 shares of the medical equipment provider’s stock valued at $44,607,000 after purchasing an additional 126,806 shares during the period. Essential Partners LLC increased its position in Boston Scientific by 2,209.1% during the first quarter. Essential Partners LLC now owns 1,016 shares of the medical equipment provider’s stock worth $64,000 after acquiring an additional 972 shares during the period. Vestor Capital LLC bought a new position in Boston Scientific during the first quarter worth $450,000. Edgestream Partners L.P. raised its stake in Boston Scientific by 340.7% during the 1st quarter. Edgestream Partners L.P. now owns 85,752 shares of the medical equipment provider’s stock valued at $5,381,000 after purchasing an additional 66,293 shares during the last quarter. Finally, Kentucky Retirement Systems raised its stake in Boston Scientific by 18.9% during the 1st quarter. Kentucky Retirement Systems now owns 110,238 shares of the medical equipment provider’s stock valued at $6,917,000 after purchasing an additional 17,562 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Barclays cut their price objective on shares of Boston Scientific from $124.00 to $96.00 and set an “overweight” rating on the stock in a research report on Thursday, April 23rd. UBS Group cut their price objective on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research report on Tuesday, March 17th. Truist Financial dropped their price target on shares of Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, April 23rd. Robert W. Baird dropped their price target on shares of Boston Scientific from $78.00 to $75.00 and set an “outperform” rating on the stock in a research report on Tuesday. Finally, Canaccord Genuity Group dropped their price target on shares of Boston Scientific from $109.00 to $71.00 and set a “buy” rating on the stock in a research report on Thursday, April 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $92.71.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.